Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204717 | 0.87 | TLR7 (0.57) | TLR7 | |
| SCHEMBL13522650 | 0.83 | KDM4E (0.47) | TLR7KDM4EALDH1A1GLAGAA | |
| SCHEMBL7209281 | 0.83 | TLR7 (0.60) | TLR7 | |
| SCHEMBL3137649 | 0.83 | TLR7 (0.45) | TLR7KDM4EALDH1A1GLAGAA | |
| SCHEMBL20343789 | 0.82 | TLR7 (0.45) | TLR7ADORA2AADORA1 | |
| SCHEMBL14944605 | 0.82 | TLR7 (0.44) | TLR7KDM4EALDH1A1GLAGAA | |
| SCHEMBL13522639 | 0.81 | KDM4E (0.51) | TLR7KDM4EALDH1A1GLAGAA | |
| SCHEMBL7205519 | 0.81 | TLR7 (0.65) | TLR7 | |
| SCHEMBL510344 | 0.81 | TLR7 (0.74) | TLR7 | |
| SCHEMBL7204280 | 0.80 | TLR7 (0.61) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-11-28 | — | — | US | disclosed |
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2776439-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-04 | — | — | EP | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| WO-2013068438-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN R&D IRELAND (IE) | 2013-05-16 | — | — | WO | disclosed |
| EP-1035123-B1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMA (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6329381-B1 | INTERFERONS, VIRICIDES AND ANTICARCINOGENIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1035123-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | PNP, ADA, HPRT1 | TLR7 295/4885ADORA2A 14/4885ADORA1 37/4885 |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | PNP, HPRT1, TYMP | TLR7 217/4885ADORA2A 17/4885ADORA1 28/4885 |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | TLR7 295/4885ADORA2A 14/4885ADORA1 37/4885 |
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | TLR7 295/4885ADORA2A 14/4885ADORA1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.